Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020
12:00am, Monday, 03'rd Aug 2020
Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020
3 “Perfect 10” Stocks To Consider During Uncertain Times
12:00am, Thursday, 30'th Jul 2020
Stocks Analysis by Investing Insights covering: Arrowhead Pharmaceuticals Inc, LKQ Corporation, Dropbox Inc. Read Investing Insights 's latest article on Investing.com
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
12:00am, Monday, 27'th Jul 2020
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
French biotech Genfit shifts gears after Phase III NASH failure
06:02pm, Thursday, 23'rd Jul 2020
The company said it was formally terminating the Phase III study of the drug elafibranor in NASH and refocus its development of the drug on another disease, primary biliary cholangitis, as well as a d
Xconomy: FDA Lifts CymaBay Drug Hold, Tests to Resume in Rare Liver Disease PBC
04:55pm, Thursday, 23'rd Jul 2020
The FDA has lifted a hold on clinical trials for an experimental CymaBay Therapeutics drug in three liver diseases, clearing the way for tests to resume
Genfit abandons late-stage trial of NASH drug elafibranor -
10:30am, Thursday, 23'rd Jul 2020
France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve
Genfit : renonce à traiter la NASH et cherche d'autres applications à l'Elafibranor | Zone bourse
08:39pm, Wednesday, 22'nd Jul 2020
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic stea
Ascletis Pharma : Bridging Study in China Completed for NASH Drug Candidate ASC40 | MarketScreener
12:31am, Monday, 20'th Jul 2020Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
12:00am, Monday, 20'th Jul 2020
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Brokerages Expect Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) to Announce -$2.42 Earnings Per Share
05:38am, Sunday, 19'th Jul 2020
Wall Street analysts expect Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) to announce earnings of ($2.42) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Madriga
Theratechnologies Inc. (THTX) Q2 2020 Earnings Call Transcript | The Motley Fool
02:30am, Thursday, 16'th Jul 2020
THTX earnings call for the period ending May 31, 2020.
